Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis: A Case Report
Drug-induced hypercholesterolemia is well known to cause side effects, such as secondary hypercholesterolemia. Many of these drugs are essential for long-term use and are difficult to replace; therefore, they are continued even when associated with hypercholesterolemia. Mesalazine is the first-line drug used for treating ulcerative colitis. We herein report a case of severe hypercholesterolemia following mesalazine administration in a patient with ulcerative colitis. In this case, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor was effective in dramatically improving severe hypercholesterolemia. Clinicians should therefore be aware of the possibility of severe hypercholesterolemia caused by mesalazine for educational purposes.
Authors
- Kazutoshi Murakami (ORCID: https://orcid.org/0000-0003-0814-8635)
- Kohei Kaku
- Shinji Kamei (ORCID: https://orcid.org/0000-0002-3980-8619)
- Takatoshi Anno (ORCID: https://orcid.org/0000-0002-7862-3385)
- Jun Wada
- Hideaki Kaneto (ORCID: https://orcid.org/0000-0001-7460-6097)
- Shuhei Nakanishi
Institutions
- Okayama University (JP)
- Kurashiki Central Hospital (JP)
- Kawasaki Medical School Hospital (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2025-12-24
- DOI
- https://doi.org/10.2169/internalmedicine.6599-25
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82